Latest news
Keep up with the latest updates
Hyperplex PCR to be presented at ISFG 2024
3 sep. 2024
News
Novel mRNA-Based Cell Type Identification Method to Be Showcased in Forensic Science
Aplex Bio appoints Rolf Ehrnström to Board of Directors
1 aug. 2024
News
Aplex Bio is pleased to welcome biotech veteran Rolf Ehrnström to its Board, bolstering leadership as the company advances in the molecular testing market.
Meet Aplex Bio at CES2024
11 dec. 2023
News
Approximately 100 Swedish companies will visit CES, covering the tech and innovation space.
Aplex Bio receives SEK 240,000 funding from Vinnova
2 nov. 2023
News
Aplex Bio receives funding from the Innovative Impact Startups autumn 2023 program
Aplex Bio recognized as top Swedish innovation on the IVA-100 list for 2023
10 maj 2023
News
The IVA-100 list is a yearly list that recognizes top research in Sweden with high scientific value and commercial potential.
hpPCR used in long-term SARS-CoV-2 surveillance study
26 nov. 2022
Publications
This study presents the learning outcomes from over two-year long monitoring of SARS-CoV-2 in Stockholm, Sweden, where hpPCR was used as proof-of-concept for variant profiling.
Aplex Bio selected among top 40 nordic life science startups to join NLS 2022
7 sep. 2022
News
APLEX Bio will be pitching the international investor community at Nordic Life Science Days in Malmö, Sweden alongside 39 other startups.
Breakthrough early detection of Omicron BA.2 in wastewater achieved with hpPCR
13 apr. 2022
News
Aplex Bio announces it has demonstrated superior performance of multiplexed COVID variant detection in wastewater, including the generally difficult to detect variant BA.2, using its next-generation hpPCR technology.
Genomeweb: In-depth feature with CEO Umear Naseem
15 mars 2022
News
Sweden's Aplex Bio Gearing up to Launch 'Hyperplexed' PCR Platform
Aplex Bio raises 14 MSEK (€1.3M) for development of its next-generation hyperplexed molecular detection technology
11 mars 2022
News
APLEX Bio announces it has raised 14 MSEK (€1.3M) for developing its massive multiplexing technology that enables detection of more than 100 biomolecules (DNA, RNA, proteins) with single molecule sensitivity in each drop of sample, without the need for sequencing or other complex instrumentation.